VIENNA — Just over half the adults without diabetes who started taking the GLP-1 semaglutide (Wegovy) for weight loss discontinued treatment within a year, with a marked drop-off in younger adults, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback